Clinical validation & evidence
What we will prove, and how.
We claim nothing about clinical performance yet, because the evidence for such a claim does not exist. This page describes the study that will produce it — and where the boundary between technical and clinical evidence runs.
Clinical validation programme in preparation · Status as of 2026-08-21
01 — The question
What a reader study answers
A second-reader tool makes no findings of its own. What it changes — if it changes anything — is how a radiologist reads. So "how accurate is the software?" is the wrong question to lead with.
The unit of evaluation is not the algorithm. It is the radiologist reading with it.
The design built for that question is the multi-reader, multi-case study, MRMC for short. Several radiologists read the same retrospective cases twice: once without the software, and — after a pause long enough that no one remembers individual cases — once with it. Because every reader reads every case both ways, the study can attribute a change in reading performance to the software itself, rather than to one sharp-eyed reader or one easy case mix.
That is the standard of evidence we consider appropriate here, and this site holds itself to it: until the study is run and independently analysed, no clinical performance claim appears on any page.
02 — The evidence ladder
Four rungs, one boundary
Technical evidence
-
exists today
Technical development
The processing and quality-control architecture that exists today: the on-premise pipeline, graded quality control with explicit abstention, per-run provenance, and the dedicated reader workstation.
-
technical benchmarking
Public-dataset evaluation
Technical benchmarking on publicly available datasets. This is engineering evidence: it informs development. No figures from it are published, and it is never clinical validation.
No clinical performance claim is made from anything above this line
Clinical and regulatory evidence
-
in preparation
Independent clinical validation
The planned reader study described below, designed with an independent reference-standard process and independent statistical input. It has not started.
-
future
Regulatory validation
The future conformity-assessment evidence package under the EU Medical Device Regulation, built on the rungs below it.
03 — The planned study
A retrospective multi-reader, multi-case study
The study in preparation uses one hundred retrospective brain MRI cases across three clinical strata: multiple sclerosis, primary brain tumours, brain metastases. Every participating radiologist reads every case twice — first unaided, later aided by Lävi Delta — with an enforced washout period between the phases.
Fig. 1 — Planned study designin preparation; final design subject to methodology review
The reference standard and the statistical analysis are planned to be independently defined and reviewed. The endpoints being prepared cover localisation performance, false-positive burden, reading time and reader confidence, alongside standalone technical performance.
We publish no sample-size justification, no power figures, no target effect sizes and no dates. Those belong in the study protocol, not on a website.
Clinical validation programme in preparation
04 — The reader environment
The study infrastructure already exists
Reader studies fail on logistics about as often as on science, so we built the reading environment first. A dedicated browser-based reader workstation exists and is deployed — not a slide deck, a running system.
What is implemented and tested in it: role-based access with two-factor authentication; the blinding gate between arms, so a reader in the unaided phase cannot reach the software's outputs even on purpose; washout enforcement between phases; structured capture of every reader response; a full audit trail; and a results export for the analysts.
The pipeline and this reader environment have been run together end to end in a full production-form deployment. That included the unglamorous half of the test: cases the pipeline rejects were confirmed to stay rejected, not slip quietly through.
05 — The boundary
What we have not proven
Clinical performance has not been established. Whether Lävi Delta changes reader performance is exactly what the planned study exists to measure, and we will not claim the answer before the study does.
Cross-vendor and cross-protocol comparison is a design goal and an explicit requirement of the validation programme. It is not an established capability, and we do not claim that the software works across scanners or protocols.
Some capabilities that exist in the software — longitudinal contrast-enhancement change detection among them — are still under technical evaluation. They are not part of any claim, and they are not in any feature list.
An empty candidate list is not evidence that nothing changed. The radiologist reads every study independently; nothing about Lävi Delta reduces that responsibility, and nothing about it is meant to.
Status as of 2026-08-21
06 — Regulatory pathway
Stages, not dates
Lävi Delta is being developed as a medical device under the EU Medical Device Regulation. The pathway below has stages and no dates — on purpose. A published timeline is a promise about other people's decisions, and we do not make promises we cannot keep ourselves.
- Product and evidence developmentcurrent stage
- Technical verificationcurrent stage
- Independent clinical validationin preparation
- Quality and technical documentationahead
- Conformity assessmentahead
- Market deploymentahead
Lävi Delta is under development. It is not CE-marked, is not available for sale, and must not be used for clinical decision-making. Information on this site describes a product in development and its planned evaluation, not the performance of a marketed medical device.
Status as of 2026-08-21